港股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

医美概念股

1,336.516

-29.392-2.15%

涨家数：2

跌家数：8

平家数：3

市盈率：- -

高：1,363.282

开：1,358.591

低：1,319.826

收：1,365.908

成交量：4,150.49万

成交额：8.20亿

市值：2,156.63亿

流通市值：1,626.25亿

数据加载中...

总览新闻资讯

四环医药11月10日获主力加仓436.6万元

时代天使11月10日获主力加仓0.0万元

从上海出发，复星医药引领中国生物医药源头创新远征

三生制药荣膺2025年度科技创新金牛奖

招银国际：医药业关注布局思路更偏稳健低估值个股机会

复星医药、华润双鹤等新设医药产业股权投资基金，出资额10亿

与复星医药“分手”后，真实生物第三次递表港股IPO

流感高发期来临，概念股反复活跃！产业链机会一览

腾讯自选股

三生制药盘中异动股价大跌6.80%报26.860港元

两亿多老人的“蛋糕”怎么分？有人拼速度有人做定制有人换战略

昊海生物科技拟使用暂时闲置募集资金进行现金管理

昊海生物科技拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权

复星医药创新引擎持续轰鸣

进博会发布大湾区细胞治疗全景图，复星凯瑞引领CAR-T疗法可及性突破

专访复星医药CEO兼总裁刘毅：聚焦神经科学领域创新，磁波刀等高端医疗器械亮相进博会

MedTrend医趋势

双擎驱动，破帕新生 | 复星医药于进博会发布帕金森病创新治疗方案

“磁波刀”是什么刀？坐着也能放疗？复星医药展台还有这些“尖货”

进博奇遇记：尖端科技“首秀” 描画未来生活

昊海生物科技(06826)拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权

昊海生物科技(06826)11月7日斥资146.18万港元回购5.31万股

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www-web.itiger.com/hans/stock/BK1593/news?page=4"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1593","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","market":"HK","secType":"PLATE","nameCN":"医美概念股","latestPrice":1336.5161,"timestamp":1763366893506,"preClose":1365.9082,"halted":0,"volume":41504908,"delay":0,"changeRate":-0.021518,"floatShares":0,"shares":0,"eps":0,"marketStatus":"未开盘","change":-29.39209,"latestTime":"11-17 16:00:00","open":1358.591,"high":1363.2819,"low":1319.8256,"amount":819763039.4,"amplitude":0.031815,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1763429400000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1763343000000,1763352000000],[1763355600000,1763366400000]],"pbRate":1.936086,"peRate":27.78233,"turnoverRate":0.002007,"increases":2,"decrements":9,"flats":2,"marketCap":215662750200,"floatMarketCap":162625286584},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1593\",,,,,undefined,":{"symbol":"BK1593","high":1363.2819,"amplitude":0.031815,"preClose":1365.9082,"low":1319.8256,"pbRate":"1.936086","latestPrice":1336.5161,"volume":41504908,"delay":0,"open":1358.591,"prevYearClose":571.87146,"prevWeekClose":1365.908,"prevMonthClose":1288.46,"prevQuarterClose":1308.644,"fiveDayClose":1258.939,"twentyDayClose":1227.28,"sixtyDayClose":1276.591,"secType":"PLATE","market":"HK","turnoverRate":0.002007,"peRate":27.78233,"marketCap":215662750200,"floatMarketCap":162625286584,"timestamp":1763366893506,"nameCN":"医美概念股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1593\",,,,undefined,":{"bkCode":"BK1593","up":2,"down":8,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1593\",pageSize:20,pageCount:4,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2582822206","title":"四环医药11月10日获主力加仓436.6万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582822206","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582822206?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:15","pubTimestamp":1762762543,"startTime":"0","endTime":"0","summary":"11月10日, 四环医药股价涨4.29%，报收1.46元，成交金额4414.6万元，换手率0.33%，振幅3.57%，量比0.84。四环医药今日主力资金净流入436.6万元，连续4日净流入，上一交易日主力净流入284.4万元。近一年数据显示，该股主力连续4日净流入后，次日上涨概率为83.33%，平均涨幅为3.27%。该股近5个交易日下跌2.01%，主力资金累计净流入684.5万元；近20日主力资金累计净流出978.5万元，其中净流出天数为10日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162017a6eef66f&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110162017a6eef66f&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","BK1600","00460"],"gpt_icon":0},{"id":"2582209918","title":"时代天使11月10日获主力加仓0.0万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582209918","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582209918?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 16:15","pubTimestamp":1762762524,"startTime":"0","endTime":"0","summary":"11月10日, 时代天使股价涨1.04%，报收68.00元，成交金额3431.6万元，换手率0.30%，振幅4.38%，量比0.48。时代天使今日主力资金净流入0.0万元，上一交易日主力净流入22.6万元。该股近5个交易日下跌1.30%，主力资金累计净流出569.1万元，其中1个交易日为股价上涨时净流出；近20日主力资金累计净流入170.8万元，其中净流入天数为7日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161711a6eef40b&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110161711a6eef40b&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["06699","BK1100","BK1587","BK1593","BK1583"],"gpt_icon":0},{"id":"2582168389","title":"从上海出发，复星医药引领中国生物医药源头创新远征","url":"https://stock-news.laohu8.com/highlight/detail?id=2582168389","media":"新民周刊","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582168389?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 15:59","pubTimestamp":1762761540,"startTime":"0","endTime":"0","summary":"2025年11月8日，第三届浦江生物医药源头创新大会在上海成功举办。复星国际联席首席执行官陈启宇作为行业领军者，上海市工商联生物医药商会会长、复星国际联席首席执行官陈启宇在大会上以《从上海出发，从本土迈向全球：中国生物医药产业的源头创新远征》为题发表演讲，提出了极具前瞻性的行业洞察。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110160046a6eee849&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110160046a6eee849&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1515","BK1593","02196"],"gpt_icon":0},{"id":"2582682237","title":"三生制药荣膺2025年度科技创新金牛奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2582682237","media":"三生制药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582682237?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 15:41","pubTimestamp":1762760487,"startTime":"0","endTime":"0","summary":"三生制药凭借其在生物医药领域卓越的科技创新能力以及对行业发展的突出贡献，成功斩获“2025年度科技创新金牛奖”。三生制药自成立以来，始终将创新视为企业发展的生命线。此次荣膺“2025年度科技创新金牛奖”，将进一步彰显三生制药在港股生物科技板块的龙头地位，提升其在国际资本市场的品牌影响力，为公司未来发展注入更强劲的动力。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110174408a6ef31af&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110174408a6ef31af&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1583","HK0000165453.HKD","BK1593","BK1161","01530"],"gpt_icon":0},{"id":"2582371841","title":"招银国际：医药业关注布局思路更偏稳健 低估值个股机会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582371841","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582371841?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 13:43","pubTimestamp":1762753386,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，招银国际发布研报称，布局思路更偏稳健，关注低估值个股机会。招银国际主要观点如下：MSCI中国医疗指数2025年初至今累计上涨59.5%，跑赢MSCI中国指数24.0%近期，医药板块有所回调，该行认为部分低估值个股具备吸引力。辉瑞管理层表示即将公布707的完整研发计划。此次医保谈判结果预计12月初公布。本轮集采的平均价格降幅并未公布。该行认为仿制药仍将长期维持较低利润率水平。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1367136.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["02367","01801","LU2097828805.USD","IE00BZ08YT58.USD","LU2488822045.USD","LU2328871848.SGD","01177","02273","BK1583","BK1593","BK1589","IE00BZ08YR35.GBP","IE00BZ08YS42.EUR","01530","BK1161","BK1219","LU2097828714.EUR","BK1191","06978","LU2097828474.EUR","ORR","BK1521","HK0000165453.HKD","LU0455707207.USD","BK1574","BK1141","02268","LU2242644610.SGD","BK1207","LU1969619763.USD","LU0502904849.HKD","LU2097828557.USD","SG9999004311.SGD","SG9999014674.SGD","BK1515","LU2097828631.EUR"],"gpt_icon":0},{"id":"2582452998","title":"复星医药、华润双鹤等新设医药产业股权投资基金，出资额10亿","url":"https://stock-news.laohu8.com/highlight/detail?id=2582452998","media":"E公司","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582452998?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 12:18","pubTimestamp":1762748311,"startTime":"0","endTime":"0","summary":"人民财讯11月10日电，企查查APP显示，近日，华润（成都）医药产业股权投资基金合伙企业（有限合伙）成立，出资额10亿元，经营范围包含：创业投资（限投资未上市企业）。企查查股权穿透显示，该企业由复星医药全资子公司上海复星医药产业发展有限公司、东阿阿胶、博雅生物、华润双鹤、江中药业等共同出资。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110121831a49635d5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110121831a49635d5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1515","BK1593","02196","BK1191"],"gpt_icon":0},{"id":"2582454389","title":"与复星医药“分手”后，真实生物第三次递表港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2582454389","media":"药研网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582454389?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 10:51","pubTimestamp":1762743089,"startTime":"0","endTime":"0","summary":"2025年11月9日，真实生物科技有限公司正式向香港交易所递交招股书。根据公开资料，这是真实生物第三次递交IPO申请：首次递表于 2022年8月4日；第二次递表于 2025年2月18日。2023 年，公司录得营收 3.44 亿元，全部来自复星医药产业。2024 年 9 月，真实生物与复星医药产业的合作正式终止，公司收入来源集中问题随之显现。此外，2022年4月，真实生物完成 B 轮融资 5.63亿元人民币，融资完成后公司估值由投前约 30亿元人民币提升至约 35.6亿元人民币。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110105541975f42f2&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110105541975f42f2&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","BK1593","BK1515","02196"],"gpt_icon":0},{"id":"2582845290","title":"流感高发期来临，概念股反复活跃！产业链机会一览","url":"https://stock-news.laohu8.com/highlight/detail?id=2582845290","media":"腾讯自选股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582845290?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 10:20","pubTimestamp":1762741207,"startTime":"0","endTime":"0","summary":"受流感高发期催化，近日流感概念股反复活跃，盘中北大医药涨停，亨迪药业涨超10%，华兰疫苗、金迪克、特一药业、华兰疫苗跟涨。上述公司均位居各自板块涨幅榜前五，我们认为其行情主要受到流感季节性高发带来的主题性投资机会驱动。中泰证券此前研报也指出，流感不等于普通感冒，高发季节传染危害不容忽视，伴随流感季的到来，建议关注相关检测、疫苗及药物公司投资机会。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111010091194fa4e24&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025111010091194fa4e24&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02607","BK1515","02196","BK1191","BK1593"],"gpt_icon":0},{"id":"2582223748","title":"三生制药盘中异动 股价大跌6.80%报26.860港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2582223748","media":"市场透视","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582223748?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 09:30","pubTimestamp":1762738228,"startTime":"0","endTime":"0","summary":"2025年11月10日早盘09时30分，三生制药股票出现波动，股价急速跳水6.80%。截至发稿，该股报26.860港元/股，成交量437.2万股，换手率0.18%，振幅2.64%。资金方面，该股资金流入873.321万港元，流出5887.27万港元。三生制药股票所在的药品行业中，整体跌幅为0.01%。其相关个股中，长风药业、山东新华制药股份、四环医药涨幅较大，振幅较大的相关个股有三生制药、信达生物、康龙化成，振幅分别为2.64%、1.70%、1.68%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110093028a6ee0f66&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110093028a6ee0f66&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","01530","BK1161","HK0000165453.HKD","BK1583"],"gpt_icon":0},{"id":"2582384529","title":"两亿多老人的“蛋糕”怎么分？有人拼速度有人做定制有人换战略","url":"https://stock-news.laohu8.com/highlight/detail?id=2582384529","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582384529?lang=zh_cn&edition=fundamental","pubTime":"2025-11-10 07:03","pubTimestamp":1762729380,"startTime":"0","endTime":"0","summary":"65岁及以上人口占比在14%至20%，中国已是深度老龄化社会。根据《2023年度国家老龄事业发展公报》，截至2023年末，中国65周岁及以上老年人口21676万人，占总人口的15.4%。陈玺撼摄调查显示，中国社区老年人肌少症的患病率为8.9%至38.8%，优质蛋白质摄入不充足是原因之一。奔波一年后，何来晨带来好消息，瘫痪助行机器人有望在海南博鳌乐城国际医疗旅游先行区加速上市，目前已有两台样机投放当地使用。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110070809a49588e5&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251110070809a49588e5&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","BK1515","BK1191","BK1593"],"gpt_icon":0},{"id":"2582898091","title":"昊海生物科技拟使用暂时闲置募集资金进行现金管理","url":"https://stock-news.laohu8.com/highlight/detail?id=2582898091","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582898091?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 11:41","pubTimestamp":1762659660,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　昊海生物科技（06826）发布公告，为提高募集资金使用效率，合理利用部分暂时闲置募集资金，在确保不影响募集资金项目建设和使用、募集资金安全且不变相改变募集资金用途的情况下，增加公司的收益，为公司及股东获取更多回报。公司计划使用不超过人民币3亿元（包含本数）的暂时闲置募集资金进行现金管理，使用期限自董事会审议通过之日起12个月内有效，在上述额度和期限内，资金可循环滚动使用。\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：卢昱君","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-09/doc-infwunpv0416892.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06826","BK1593","BK1161"],"gpt_icon":0},{"id":"2582589899","title":"昊海生物科技拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2582589899","media":"新浪港股","labels":["shareholding","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582589899?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 11:01","pubTimestamp":1762657260,"startTime":"0","endTime":"0","summary":"　　昊海生物科技发布公告，于2025年11月7日，本公司的全资子公司上海昊海医药科技作为受让方与转让方张先生、深圳九思及深圳百纳订立股权转让补充协议，转让方同意向受让方出售目标公司余下20%股权，对价为人民币7400万元。收购事项完成后，本集团将持有目标公司100%股权。　　本集团自2016年11月及2023年2月分别收购目标公司60%及20%股权后，致力稳步进军眼科高值耗材领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/ggscyd/2025-11-09/doc-infwunpw8897668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,merge","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06826","BK1593","300832","BK1161","BK0239"],"gpt_icon":0},{"id":"2582089843","title":"复星医药创新引擎持续轰鸣","url":"https://stock-news.laohu8.com/highlight/detail?id=2582089843","media":"药渡","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582089843?lang=zh_cn&edition=fundamental","pubTime":"2025-11-09 07:31","pubTimestamp":1762644662,"startTime":"0","endTime":"0","summary":"创新战略持续推进，2025年上半年，复星医药创新药品收入超43亿元，同比增长14.26%。HLX43是全球范围内稀有的款PD-L1ADC，目前仅3款PD-L1 ADC进入临床，有望成为复星医药管线中未来的支柱品种。2021年6月，复星医药从美国Kite引进Yescarta技术，该产品于2021年获NMPA的上市批准。2024年9月，复星医药宣布出资2700万美元受让Kite Pharma持有的复星凯瑞50%的股权。自2023年起，复星医药开始强调“瘦身”与聚焦，这两年来持续推进非战略非核心资产的退出和整合","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109073537a6ebcb69&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251109073537a6ebcb69&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1191","HK0000165453.HKD","02696","BK1593","02196","BK1515","BK1161"],"gpt_icon":0},{"id":"2582862629","title":"进博会发布大湾区细胞治疗全景图，复星凯瑞引领CAR-T疗法可及性突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862629","media":"复星医药","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582862629?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 23:34","pubTimestamp":1762616092,"startTime":"0","endTime":"0","summary":"随后，会议聚焦于大湾区细胞治疗的具体实践与患者获益。大湾区细胞治疗的愿景正通过跨境合作加速落地。今年，复星凯瑞在大湾区的细胞治疗布局也取得系列突破。奕凯达于2023年9月在澳门获批上市后，复星凯瑞于2024年5月与澳门镜湖医院共建当地首家CAR-T细胞治疗中心。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108234447a6eb45a8&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108234447a6eb45a8&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["02196","00656","BK1191","BK1515","BK1593"],"gpt_icon":0},{"id":"2582626268","title":"专访复星医药CEO兼总裁刘毅：聚焦神经科学领域创新，磁波刀等高端医疗器械亮相进博会","url":"https://stock-news.laohu8.com/highlight/detail?id=2582626268","media":"MedTrend医趋势","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582626268?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 19:09","pubTimestamp":1762600162,"startTime":"0","endTime":"0","summary":"复星医药在CNS领域积极探索创新方案：脑磁图仪负责功能影像诊断，精准定位病灶；磁波刀通过超声聚焦的磁场实现无创治疗；欧捷能等药物控制症状波动，形成“药械协同”的独特优势。复星医药并未止步于现有产品，后期还将在神经系统领域布局更多创新药物和诊疗科技。刘毅最后表示，复星医药将持续以患者为中心，在“创新+全球化”的道路上持续深耕，让神经科学领域的诊疗创新方案，真正成为全球患者的健康福音。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108192051a6eae648&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108192051a6eae648&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["09996","02196","09997","BK1593","BK1191","BK1100","BK1515","BK1583","BK1222","BK1574"],"gpt_icon":0},{"id":"2582862625","title":"双擎驱动，破帕新生 | 复星医药于进博会发布帕金森病创新治疗方案","url":"https://stock-news.laohu8.com/highlight/detail?id=2582862625","media":"复星万邦","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582862625?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 18:20","pubTimestamp":1762597214,"startTime":"0","endTime":"0","summary":"上海，2025 年 11 月 6 日—— 在第八届中国国际进口博览会上，复星医药以“双擎驱动，破帕新生”为主题，成功举办帕金森病创新治疗方案联合发布会。活动于 2025 年 11 月 6 日举行，通过专家对话、趋势分享与联合发布等多种形式，全面展示了复星医药在帕金森病领域的前沿布局，包括“奥吡卡朋”与复星医视特“磁波刀”等创新治疗方案，体现了企业以患者为中心、持续推动医疗健康事业发展的坚定承诺。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108183046a4927599&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108183046a4927599&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","02196","BK1191","BK1515"],"gpt_icon":0},{"id":"2582486262","title":"“磁波刀”是什么刀？坐着也能放疗？复星医药展台还有这些“尖货”","url":"https://stock-news.laohu8.com/highlight/detail?id=2582486262","media":"新民晚报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582486262?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 09:45","pubTimestamp":1762566309,"startTime":"0","endTime":"0","summary":"本届进博会上，复星医药展示了全球领先的脑部疾病创新解决方案。这正是复星医药在本届进博会上首次展出的立式粒子室内治疗系统。复星医药将本届进博会作为该产品的全球首展舞台，足见其对中国市场乃至全球影响力的重视。从让患者“坐着”接受粒子放疗的立式治疗系统，到其他集中展示的创新药品与合作成果，复星医药的展台成为进博会推动全球前沿医疗科技从“展品变商品”、惠及中国患者的一个生动缩影。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108094801a6ea0378&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108094801a6ea0378&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1593","BK1515","BK1191","02196"],"gpt_icon":0},{"id":"2582621862","title":"进博奇遇记：尖端科技“首秀” 描画未来生活","url":"https://stock-news.laohu8.com/highlight/detail?id=2582621862","media":"环球网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582621862?lang=zh_cn&edition=fundamental","pubTime":"2025-11-08 07:01","pubTimestamp":1762556460,"startTime":"0","endTime":"0","summary":"走进第八届中国国际进口博览会展区，高科技催生的新产品琳琅满目。11月5日至10日，第八届进博会在上海举办，155个国家、地区和国际组织参与，4108家境外企业参展，整体展览面积超过43万平方米，规模创下新高。在第八届进博会汽车及智慧出行展区，没有方向盘和踏板的特斯拉Cybercab无人驾驶电动车迎来亚太首秀。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108075404a4916966&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN20251108075404a4916966&s=b","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tencent","symbols":["BK1222","BK1574","BK1593","02196","BK1583","BK1515","BK1191","09997","BK1100","09996"],"gpt_icon":0},{"id":"2581949881","title":"昊海生物科技(06826)拟7400万元收购深圳市新产业眼科新技术有限公司余下20%股权","url":"https://stock-news.laohu8.com/highlight/detail?id=2581949881","media":"智通财经","labels":["corporation","merge"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581949881?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 22:50","pubTimestamp":1762527058,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技 发布公告，于2025年11月7日，本公司的全资子公司上海昊海医药科技作为受让方与转让方张先生、深圳九思及深圳百纳订立股权转让补充协议，转让方同意向受让方出售目标公司余下20%股权，对价为人民币7400万元。收购事项完成后，本集团将持有目标公司100%股权。本集团自2016年11月及2023年2月分别收购目标公司60%及20%股权后，致力稳步进军眼科高值耗材领域。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation,merge","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","BK0239","06826","300832","BK1593"],"gpt_icon":0},{"id":"2581027540","title":"昊海生物科技(06826)11月7日斥资146.18万港元回购5.31万股","url":"https://stock-news.laohu8.com/highlight/detail?id=2581027540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2581027540?lang=zh_cn&edition=fundamental","pubTime":"2025-11-07 19:59","pubTimestamp":1762516769,"startTime":"0","endTime":"0","summary":"智通财经APP讯，昊海生物科技(06826)发布公告，于2025年11月7日，该公司斥资146.18万港元回购5.31万股股份，每股回购价格为27.34-27.6港元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1366821.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1593","06826","BK1161"],"gpt_icon":0}],"pageSize":20,"totalPage":7,"pageCount":4,"totalSize":123,"code":"91000000","status":"200"}]}}